1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,400 | 7,060 | 05.06. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SELVITA Aktie jetzt für 0€ handeln | |||||
| 27.05. | Asseco SEE and BNP Paribas to join mWIG40 index, Grenevia and Selvita to leave (opinion) | 6 | PAP | ||
| 22.05. | Selvita pharma sees slowdown in contracting; H2 marked by uncertainty | 1 | PAP | ||
| 22.05. | Selvita pharma backlog for 2025 at PLN 249.9 mln | 1 | PAP | ||
| 22.05. | Selvita pharma posts PLN 1.0 mln attributable net loss in Q1 '25, below expectations | 2 | PAP | ||
| 27.03. | Selvita S.A.: Selvita Reports Rebound in H2 2024 and 11% Increase in Backlog for 2025 | 237 | PR Newswire | KRAKOW, Poland, March 27, 2025 /PRNewswire/ -- Selvita S.A. (WSE: SLV), one of Europe's leading preclinical CROs, has announced its financial results for 2024... ► Artikel lesen | |
| 21.11.24 | Selvita Reports Significant Recovery in H2 2024, Sees Promising Outlook for the Future | 181 | PR Newswire | KRAKÓW, Poland, Nov. 21, 2024 /PRNewswire/ -- Selvita S.A. (WSE: SLV), one of the leading preclinical contract research organizations in Europe, has published... ► Artikel lesen | |
| 24.09.24 | Selvita S.A.: Selvita reports growing sales in Q2 and Q3, and projects increased profitability in H2 2024 | 420 | PR Newswire | KRAKÓW, Poland, Sept. 24, 2024 /PRNewswire/ -- Selvita S.A. (WSE: SLV), one of the leading preclinical contract research organizations in Europe, has published its financial results for Q2 2024... ► Artikel lesen |
7 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | 0,079 | -0,13 % | Palatin Technologies Q1 Net Loss Narrows On Lower Expenses | WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTNT.PK), a biopharmaceutical company, on Wednesday reported narrower net loss in its first quarter with sharply lower operating expenses.Palatin... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 3,240 | -1,82 % | COSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Shareholders | Reconstituted Board to Revitalize COSCIENS TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI; TSX: CSCI) today announced that it has entered into a resolution agreement... ► Artikel lesen | |
| AMYRIS | - | - | Amyris gains sole control of Brazilian fermentation facility | ||
| HALOZYME THERAPEUTICS | 46,710 | -1,00 % | Meridian Growth Fund Trimmed Halozyme Therapeutics (HALO) for the Valuation Discipline | ||
| ABCELLERA BIOLOGICS | 2,045 | -3,76 % | Why AbCellera Biologics Stock Raced Nearly 6% Higher Today | ||
| GLOW LIFETECH | 0,030 | 0,00 % | Glow LifeTech Corp.: Glow Lifetech Reports 238% YoY Revenue Growth and Near-Breakeven EBITDA in Q1 2025, Marking Third Straight Quarter of 40%+ Sequential Revenue Growth | Toronto, Ontario--(Newsfile Corp. - June 2, 2025) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to report its financial results for the first quarter... ► Artikel lesen | |
| BIO-RAD LABORATORIES | 189,00 | -2,88 % | Bio-Rad Laboratories-Aktie im Fokus des Cantor Fitzgerald-Berichts | ||
| AVID BIOSERVICES | 12,100 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 05.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 05.02.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 05.02.2025ISIN NameCA75525M1095 RAZOR... ► Artikel lesen | |
| BIOLINERX | 3,283 | -100,00 % | BioLineRx Ltd: BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting | - 4 of 11 PDAC patients in the pilot phase remained progression free at over one year
- Poster presentation on Saturday, May 31 st
TEL AVIV, Israel, May 30, 2025... ► Artikel lesen | |
| WHITEHAWK THERAPEUTICS | 1,490 | 0,00 % | Whitehawk Therapeutics, Inc.: Whitehawk Reports First Quarter 2025 Financial Results and Recent Highlights | MORRISTOWN, N.J., May 8, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to... ► Artikel lesen | |
| PARATEK PHARMACEUTICALS | - | - | Paratek Pharmaceuticals, Inc.: Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE in Chronic Rhinosinusitis (CRS) | Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ~10-million-patient marketAcquisition advances Paratek's vision... ► Artikel lesen | |
| MINERVA NEUROSCIENCES | 1,600 | +0,63 % | Minerva Neurosciences, Inc: Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates | BURLINGTON, Mass., May 13, 2025(Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates... ► Artikel lesen | |
| APPLIED THERAPEUTICS | 0,341 | +3,53 % | Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting | Slowing of progression of disease observed via MRI at 24 months Improvements in outcomes and reduction in sorbitol maintained through 24 months Statistically significant correlation between absolute... ► Artikel lesen | |
| GEOVAX LABS | 2,685 | -100,00 % | Nitches, inc: Nitches Inc. Updates Shareholders on Amazon Integration, GovX Integration, and 2025 Growth Strategy for InTheZone Labs | LAS VEGAS, NV / ACCESSWIRE / December 18, 2024 / Nitches Inc. (OTC PINK:NICH) is pleased to share key updates regarding the recent strides made with its InTheZone Labs brand, highlighting successful... ► Artikel lesen | |
| COCRYSTAL | 1,470 | -0,68 % | Cocrystal Pharma, Inc. - 8-K, Current Report |
Das Unternehmen SELVITA SA kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 6,900 Euro und damit +0,29 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SELVITA SA finden Sie auf Wallstreet Online.